Literature DB >> 22266935

Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment.

Linn Woelber1, Christine Eulenburg, Matthias Choschzick, Andreas Kruell, Cordula Petersen, Friederike Gieseking, Fritz Jaenicke, Sven Mahner.   

Abstract

OBJECTIVE: Lymph node metastases are the most important prognostic factor for recurrence and survival in vulvar cancer. However, information regarding the impact of the number of positive nodes in vulvar cancer is inconsistent, and so are recommendations when to apply adjuvant radiotherapy.
METHODS: One hundred fifty-seven consecutive patients with primary squamous cell cancer of the vulva treated at our center were analyzed. All patients underwent primary surgery by triple incision resulting in complete tumor resection.
RESULTS: Median age was 61 years; 49 patients (31%) had lymph node metastases; 21 patients had 1, 13 had 2, and 15 had more than 2 positive lymph nodes. Thirty-two percent of the patients received adjuvant radiotherapy. The risk of lymph node metastases increased with age, greater tumor size, deeper invasion, and higher tumor grade. Median follow-up was 36 months; 23 patients (14.6%) developed disease recurrence (61% vulva, 35% groins, and 4% both). Compared with node-negative patients, survival in all node-positive patients was significantly impaired (P < 0.001; disease-free patients after 2 years: 88% in node-negative patients; 60%, 43%, and 29% in patients with 1, 2, and >2 affected nodes, respectively), whereas no significant difference between the node-positive subgroups could be demonstrated regarding disease-free survival. In multivariate analysis, lymph node status remained the most important prognostic factor regarding disease-free survival, but the effect of positive nodes differed significantly dependent on adjuvant treatment (P = 0.001). In patients without adjuvant radiotherapy to the groins/pelvis, the number of metastatic nodes was highly relevant for prognosis (hazard ratio, 1.752; P < 0.001), whereas this effect disappeared in patients who were treated with adjuvant radiotherapy (hazard ratio, 0.972; P = 0.828).
CONCLUSIONS: The negative impact of lymph node metastases is already evident in patients with only 1 affected lymph node. In patients receiving adjuvant radiotherapy, the negative effect of additional lymph node metastases is reduced; adjuvant treatment might therefore be beneficial in patients with only 1 positive node.

Entities:  

Mesh:

Year:  2012        PMID: 22266935     DOI: 10.1097/IGC.0b013e31823eed4c

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  23 in total

1.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

2.  Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer.

Authors:  Cameron W Swanick; Patricia J Eifel; Jinhai Huo; Larissa A Meyer; Grace L Smith
Journal:  Gynecol Oncol       Date:  2017-05-12       Impact factor: 5.482

3.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

Review 4.  New Directions in Vulvar Cancer Pathology.

Authors:  Anthony Williams; Sheeba Syed; Shireen Velangi; Raji Ganesan
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

5.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.

Authors:  Deyin Xing; Yuehua Liu; Hyeon Jin Park; Inji Baek; Hung Tran; Gloria Cheang; Jorge Novo; Jessica Dillon; Andres Matoso; Emily Farmer; Max A Cheng; Ya-Chea Tsai; Kara Lombardo; Michael G Conner; Russell Vang; Chien-Fu Hung; Tzyy-Choou Wu; Wei Song
Journal:  Hum Pathol       Date:  2019-08-19       Impact factor: 3.466

6.  Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose.

Authors:  Karishma Khullar; Tomas Patrich; Salma K Jabbour; Lara Hathout
Journal:  Appl Radiat Oncol       Date:  2022-03

Review 7.  Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Authors:  Deyin Xing; Oluwole Fadare
Journal:  Semin Diagn Pathol       Date:  2020-09-25       Impact factor: 3.464

8.  Prognosis of vulval cancer with lymph node status and size of primary lesion: A survival study.

Authors:  Pankaj Deka; Debabrata Barmon; Sushrata Shribastava; Amal Chandra Kataki; J D Sharma; M Bhattacharyya
Journal:  J Midlife Health       Date:  2014-01

9.  Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

Authors:  Sven Mahner; Julia Jueckstock; Felix Hilpert; Petra Neuser; Philipp Harter; Nikolaus de Gregorio; Annette Hasenburg; Jalid Sehouli; Annika Habermann; Peter Hillemanns; Sophie Fuerst; Hans-Georg Strauss; Klaus Baumann; Falk Thiel; Alexander Mustea; Werner Meier; Andreas du Bois; Lis-Femke Griebel; Linn Woelber
Journal:  J Natl Cancer Inst       Date:  2015-01-24       Impact factor: 13.506

10.  Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact.

Authors:  Hari Prasad Dhakal; Jahn M Nesland; Mette Førsund; Claes G Trope; Ruth Holm
Journal:  BMC Cancer       Date:  2013-10-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.